[Click eStock] "Genomictree, Focus on EarlyTech B Final Clinical Results Announcement in June"

Hana Securities analyzed on the 29th that the announcement of the final clinical trial report for EarlyTecB in June is expected to act as a trigger for the stock price of Genomictree.

Choi Jae-ho, a researcher at Hana Securities, stated in the report on the same day, "Due to large-scale clinical trial expenses, this year's performance is expected to be somewhat sluggish," but added, "The stock price momentum remains intact due to the smoothly progressing processes."

Researcher Choi said, "Starting next year, with the domestic health insurance listing of EarlyTecB and C, the company will enter a phase of substantial earnings generation," and forecasted, "Looking at the processes sequentially, the announcement of the final clinical trial report for EarlyTecB in June will act as a trigger for the stock price."

He also explained, "Given the announcement of efficacy data such as high sensitivity and specificity, there is a high possibility of being valued higher than the current valuation," and added, "Subsequently, various events are prepared, including new medical technology and health insurance listing, completion of large-scale confirmatory clinical trials in China, and full-scale entry into the U.S. market."

He further predicted, "As the processes for high earnings growth proceed sequentially, the company's attention will increase."

This content was produced with the assistance of AI translation services.